DLBCL

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We encourage you to take a look around at all the cutting-edge information, education, research, and other resources we’ve curated to empower your practice in this disease space. If you have any feedback or questions, please contact jadpro-editor@conexiant.com

Katherine L. Byar, MSN, APN, BC, BMTCN

Oncology/ Hematology Nurse Practitioner

Fred & Pamela Buffett Cancer Center

Nebraska Medicine
Omaha, Nebraska

DLBCL Resource Center

Interview with Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP: Improving Access to Bispecific Antibodies in the Community for DLBCL: Challenges and Opportunities

Lymphoma Research Foundation

DLBCL Trials on Clinicaltrials.gov

International Prognostic Index (IPI) Calculator

Leukemia & Lymphoma Society

NCCN Guidelines on Diffuse Large B-Cell Lymphoma

Rare Disease Advisor

Epcoritamab combination shows strong responses in R/R DLBCL

Blood Advances

An AI model classifies risks of early relapse post-CAR T cell therapy in a multi-center real-world population with DLBCL

Critical Reviews in Oncology/Hematology

From R-CHOP to revolution: How CAR T-cells, ADCs, and bispecific antibodies are transforming DLBCL treatment

Cancer Research and Treatment

BTG1 mutation correlates with inferior prognosis in diffuse large B-cell lymphoma

Blood Neoplasia

Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis

Cancer Cell

Large B cell lymphoma microenvironment archetype profiles

2025 American Society of Clinical Oncology Annual Meeting Abstract

Impact of CAR T cell therapy product in the clinical outcome of patients with relapsed/refractory diffuse large B-cell lymphoma

2025 American Society of Clinical Oncology Annual Meeting Abstract

Glofitamab plus gemcitabine and oxaliplatin (Glofit-GemOx) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 2-year (yr) follow-up of STARGLO

2025 American Society of Clinical Oncology Annual Meeting Abstract

Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study

HemaSphere

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Primary Diffuse Large B-Cell Lymphoma of the Bone

Unraveling the Enigma: A Case Study on Primary CNS Lymphoma

Relapsed DLBCL After CAR T-Cell Therapy

Take our brief survey to share how your practice manages DLBCL

Fast Facts #12: Long-Term Survivorship